<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <ref-type name="Journal Article">17</ref-type>
      <contributors>
        <authors>
          <author>K. Mahboob</author>
          <author>J. A. Khan</author>
          <author>M. S. Khan</author>
        </authors>
      </contributors>
      <titles>
        <title>PREVALENCE, CHEMOTHERAPY AND HAEMATOLOGY OF STRONGYLOSIS IN HORSES OF DISTRICT LAYYAH</title>
        <secondary-title>Journal of Animal and Plant Sciences</secondary-title>
        <alt-title>JAPS</alt-title>
      </titles>
      <dates><year>2008</year><pub-dates><date>2008/08/01</date></pub-dates></dates>
      <volume>18</volume>
      <number>4</number>
      <pages>NA</pages>
      <isbn>1018-7081</isbn>
      <electronic-resource-num>NA</electronic-resource-num>
      <abstract>&lt;p&gt;The present study had been planned to estimate the infection rate of strongylosis, comparative efficacy of four anti-parasitic drugs; Closantel (Endoectiven), Mebendazole (Vermox), Neem (Azadirachta indica A . Juss) dried leaves and Oxfendazole (Systamex) and effect of strongyloids on different blood parameters in horses of district Layyah. Horses&amp;rsquo; faecal samples were processed coprollogically for strongyloids infection with the prevalence of 57.47%. The horses positive for the infestation were randomly divided into six groups A, B, C, D, E and F each comprising of 10 animals. Group A was treated with Closantel (Endoectiven), group B with Mebendazole (Vermox), group C with Neem (Azadirachta indica A. Juss) dried leaves, group D with Oxfendazole (Systamex), group E was kept as positive control (infected untreated) and group F was kept as negative control (uninfected untreated). The percentage efficacy of different treatments was 0 and 0%, 91.93 and 95.16%, 6.89 and 8.62%, 96.82 and 98.14% after days 7 and 14 post medication, in groups A, B, C and D respectively. Horses affected with strongylosis showed greater reduction in haematological parameter. On day zero total erythrocyte count values were 4.50, 4.09, 4.90, 3.85, 3.87 and 8.00 &amp;times; 106 /&amp;mu;l in group A, B, C, D, E and F, respectively while on day 7 (post treatment) the values were 4.35, 7.47, 5.02, 6.20, 3.78 and 8.00 &amp;times; 106 /&amp;mu;l in group A, B, C, D, E and F respectively. The values on day 14 (post treatment) were 4.25, 9.10, 5.10, 6.80, 3.69 and 8.00 x 106/&amp;mu;l in group A, B, C, D, E and F respectively. Packed cell volume (PCV) values were 32.50, 31.29, 31.02, 32.80, 32.60 and 37.00% in group A, B, C, D, E and F, respectively on day zero (pre treatment), while the values on day 7 were 31.70, 34.35, 32.10, 36.40, 31.95 and 37.00% in group A, B, C, D, E and F respectively. The values on day 14 (post treatment) in group A, B, C, D, E and F were 31.15, 40.10, 32.12, 39.95, 31.05 and 37.00%, respectively. Haemoglobin estimated values on day zero (pre treatment) in group A, B, C, D, E and F were 8.85, 9.28, 9.35, 9.64, 9.70 and 12.00 g/dl, respectively, while theses values in group A, B, C, D, E and F on day 7 (post treatment) were 8.65, 10.35, 9.45, 11.20, 9.18 and 12.00 g/dl respectively. Similarly the values on day 14 (post treatment) were 8.10, 11.05, 9.49, 12.40, 8.72 and 12.00 g/dl in group A, B, C, D, E and F, respectively.&lt;/p&gt;</abstract>
      <keywords><keyword>Strongylosis, Strongyloids, Haematology</keyword></keywords>
      <publisher>Pakistan Agricultural Scientists Forum</publisher>
      <urls><related-urls><url>https://thejaps.org.pk/AbstractView.aspx?mid=2008-JAPS-404</url></related-urls></urls>
    </record>
  </records>
</xml>
